UB-612

UB-612 is a protein subunit vaccine developed by COVAXX, a division of United Biomedical, for the prevention of COVID-19. The vaccine is designed to target the SARS-CoV-2 virus, which causes COVID-19.

Development

UB-612 is a synthetic peptide-based vaccine that uses a SARS-CoV-2 spike protein's receptor-binding domain (RBD) to stimulate an immune response. The vaccine also includes an adjuvant, known as Advax, to enhance the immune response.

The vaccine's development began in early 2020, following the outbreak of the COVID-19 pandemic. In preclinical trials, the vaccine demonstrated a strong immune response and was found to be safe and well-tolerated.

Clinical Trials

Phase I and II clinical trials for UB-612 were conducted in Taiwan, with the results showing that the vaccine was safe and effective in inducing an immune response against SARS-CoV-2. The vaccine is currently in Phase III clinical trials, which are being conducted in multiple countries, including the United States, Brazil, and India.

Efficacy

While the final efficacy data for UB-612 is not yet available, preliminary results from Phase I and II trials suggest that the vaccine is capable of inducing a robust immune response against SARS-CoV-2. The vaccine has also been found to be well-tolerated, with no serious adverse events reported.

Distribution

Upon receiving regulatory approval, COVAXX plans to produce up to one billion doses of the UB-612 vaccine in 2021. The company has also entered into agreements with multiple countries for the distribution of the vaccine, once approved.

See Also

• COVID-19 vaccine
• COVID-19 pandemic
• SARS-CoV-2
• COVAXX
• United Biomedical

   This article is a  stub. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!